Jonathan Rubin, MD, MBA
Esta página aún no está disponible en tu idioma.
Jonathan Rubin, MD, MBA, is Chief Medical Officer and Senior Vice President of Research & Development at Supernus Pharmaceuticals. His relevance to the botulinum toxin industry comes from medical and R&D leadership around Supernus’s CNS portfolio, including Myobloc / Neurobloc.
Rubin’s role should not imply that Supernus developed Myobloc from origin. It explains current medical and development leadership at the company that now commercializes Myobloc in the United States.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Supernus Pharmaceuticals |
| Current role | Chief Medical Officer and Senior Vice President, Research & Development |
| Industry relevance | Supernus medical and R&D leadership for CNS portfolio interpretation |
| Relevant company | Supernus Pharmaceuticals |
| Relevant brand | Myobloc / Neurobloc |
| Market context | Therapeutic CNS portfolio and type B toxin label context |
Career Notes
Section titled “Career Notes”- Supernus identifies Rubin as Chief Medical Officer and Senior Vice President of Research & Development.
- Supernus states that he has held the CMO / R&D role since January 1, 2021.
- Supernus lists Myobloc among its commercial products for neurological conditions.
- Myobloc’s U.S. prescribing information identifies the product as rimabotulinumtoxinB and preserves product-specific indication and unit limits.
Medical Leadership Context
Section titled “Medical Leadership Context”Rubin matters because Myobloc is a therapeutic type B product, not an aesthetic type A product. Its interpretation depends on product-specific labeling, safety language, and medical context rather than broad neuromodulator marketing shorthand.
The medical-leadership link is useful for company mapping only. It should not be used to infer new indications, off-label use, comparative efficacy, or unit conversion across botulinum toxin products.
Activity and Public Context
Section titled “Activity and Public Context”Rubin’s Supernus and Myobloc relevance is medical and R&D leadership rather than commercial leadership. Jack A. Khattar anchors Supernus company leadership, while Todd Horich, Ph.D., MBA anchors commercial leadership.